EUCTR2008-000781-23-GB进行中（未招募）不适用
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with Radiotherapy, in Patients with Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy - Zalutumumab in combination with radiotherapy in SCCHN patients ineligible for platinum based chemoth
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Genmab A/S
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Patients with histologically or cytologically confirmed diagnosis of locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx stage III, IVa or IVb
- •2) Measurable disease defined as one or more target lesions according to RECIST based on CT scan or MRI and clinical evaluation
- •3) Eligible for intended curative radiotherapy
- •4) Patients considered ineligible for platinum based chemotherapy based on investigator’s judgment
- •5) Age > 18 years
- •6) Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Prior radiotherapy to the head and neck area
- •2) Prior chemotherapy administered for cancer in the head and neck area
- •3) Prior targeted therapy (e.g. EGFr antibodies or EGFr inhibitors)
- •4) Received the following treatments within 4 weeks prior to Visit 2:
- •a. Retinoic acid
- •b. Other immunosuppressive drugs (e.g. drugs interfering with the functions of T cells, IL-2 or equivalent)
- •c. Any non-marketed drug substance
- •5) Past or current malignancy other than SCCHN, except for:
- •Cervical carcinoma Stage 1B or less
- •Non-invasive basal cell skin carcinoma
- •Squamous cell skin carcinoma
- •Stage 1 or 2 treated prostate cancer with PSA in the normal range for >2 years post treatment
- •Malignant melanoma with a complete response duration of > 10 years
- •Other cancer diagnoses with a complete response duration of > 5 years
- •6) Metastatic SCCHN disease
- •7) Chronic or current infectious disease such as, but not limited to, chronic renal infection, and tuberculosis
- •8) Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months before Visit 1, congestive heart failure, and arrhythmia requiring anti-arrhythmic therapy, with the exception of extra systoles or minor conduction abnormalities
- •9) Significant concurrent, uncontrolled medical condition including, but not limited to, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease considered to preclude trial treatment and/or compliance according to the Investigator’s opinion, or any other condition preventing therapy according to the Investigator’s opinion
- •10) Known HIV positive
- •11) Known active hepatitis B and/or hepatitis C
- •12) Screening laboratory values:
- •Neutrophils < 1.5 x 109/L
- •Platelets < 100 x109/L
- •Hemoglobin < 6 mmol/L
- •13) Current participation in any other interventional clinical study
- •14) Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency, or psychological disorder)
- •15) Known or suspected hypersensitivity to components of the investigational medicinal product
- •16) Breast feeding women or women with a positive pregnancy test at screening blood sample
- •17) Males not willing to use adequate contraception during study and for 12 months after last dose of zalutumumab or women of childbearing potential not willing to use adequate contraception as hormonal birth control or intrauterine device during study and for 12 months after last dose of zalutumumab
研究者
相似试验
进行中（未招募）
不适用
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with Radiotherapy, in Patients with Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy - Zalutumumab in combination with radiotherapy in SCCHN patients ineligible for platinum based chemothStage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based ChemotherapyMedDRA version: 9.1Level: LLTClassification code 10023860Term: Laryngeal squamous cell carcinoma stage IIIMedDRA version: 9.1Level: LLTClassification code 10023861Term: Laryngeal squamous cell carcinoma stage IVEUCTR2008-000781-23-BEGenmab A/S30
进行中（未招募）
1 期
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with Radiotherapy, in Patients with Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy - Zalutumumab in combination with radiotherapy in SCCHN patients ineligible for platinum based chemothStage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based ChemotherapyMedDRA version: 9.1Level: LLTClassification code 10023860Term: Laryngeal squamous cell carcinoma stage IIIMedDRA version: 9.1Level: LLTClassification code 10023861Term: Laryngeal squamous cell carcinoma stage IVEUCTR2008-000781-23-FRGenmab A/S36
进行中（未招募）
1 期
An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibody, in adult patients with active rheumatoid arthritis who previously received ofatumumab or placebo in Trial Hx-CD20-403 - Long-term efficacy and safety of repeated ofatumumab courses in RA patients who were in Hx-CD20-403Rheumatoid ArthritisEUCTR2007-004878-31-GBGlaxoSmithKline Research & Development Ltd
进行中（未招募）
不适用
An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibody, in adult patients with active rheumatoid arthritis who previously received ofatumumab or placebo in Trial Hx-CD20-403 - Long-term efficacy and safety of repeated ofatumumab courses in RA patients who were in Hx-CD20-403MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-004878-31-DKGlaxoSmithKline Research & Development Ltd264
进行中（未招募）
不适用
An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibody, in adult patients with active rheumatoid arthritis who previously received ofatumumab or placebo in Trial Hx-CD20-403 - Long-term efficacy and safety of repeated ofatumumab courses in RA patients who were in Hx-CD20-403MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-004878-31-HUGlaxoSmithKline Research & Development Ltd.264